GLP-1 Drugs Like Ozempic Linked to 30% Lower Breast Cancer Risk in Major Study
A study of 110,000+ women found GLP-1 users had ~30% lower breast cancer risk, sparking plans for clinical trials.
20 articles
A study of 110,000+ women found GLP-1 users had ~30% lower breast cancer risk, sparking plans for clinical trials.
Breakthrough blood test combining four biomarkers catches deadly pancreatic cancer early when treatment works best, detecting 87.5% of stage I/II cases.
Breakthrough non-invasive device offers new hope for pancreatic cancer patients with at-home treatment option.
New study finds 27% of patients with treatment-resistant hypertension have elevated cortisol levels that could explain medication failures.
New study shows PCSK9 inhibitor prevents cardiovascular events in high-risk diabetes patients without existing heart disease.
New AI tool automatically identifies cells with chromosomal defects that may lead to cancer, helping scientists study how cancer begins.
Australian biotech company creates targeted treatment that attacks malignant plasma cells while sparing healthy ones in multiple myeloma patients.
New trial data reveals AstraZeneca's experimental in vivo CAR-T therapy showed early responses in multiple myeloma patients but resulted in one death.
Updated guidelines recommend cholesterol screening in childhood and tracking genetic factors like lipoprotein(a) for personalized prevention.
Researchers developed an AI system that identifies gene patterns predicting which cancers will spread, potentially transforming treatment decisions.
Revolutionary CRISPR technique bypasses lab manufacturing by programming immune cells to fight cancer directly in the body.
McGill scientists boosted NK cell cancer-killing power using reversible drug treatment, targeting leukemia, glioblastoma, and triple-negative breast cancer.
New research reveals colorectal cancer has distinct microbial communities that could improve diagnosis and personalized treatment approaches.
Scientists discover D-cysteine selectively targets cancer cells by disrupting their energy production without harming normal cells.
Key biotech companies developing T cell engager therapies that redirect immune cells to fight cancer more effectively.
A short pre-surgery course of pembrolizumab left zero relapses in colorectal cancer patients after 33 months โ reshaping treatment strategy.
Single injection of engineered virus kills glioblastoma cells and activates immune system, extending patient survival in clinical trial.
A new imaging breakthrough reveals how immune cells target cancer with nanoscale precision, opening doors for better immunotherapy.
A Swiss study of 100,000 cases over 40 years reveals colorectal cancer rising steadily in younger adults, with late diagnoses alarmingly common.
A newly identified molecule called SLAMF6 exhausts cancer-fighting T cells from within โ and blocking it may revive failed immunotherapies.